Feature | May 03, 2010| Dave Fornell

Companies Developing Drug-Eluting Balloons

The Paccocath coating of the B.Braun SeQuent Please DEB uses contrast media to separate and evenly distribute the paclitaxel molecules over the surface of the balloon. The anti-proliferative drug helps prevent restenosis.

The Paccocath coating of the B.Braun SeQuent Please DEB uses contrast media to separate and evenly distribute the paclitaxel molecules over the surface of the balloon. The anti-proliferative drug helps prevent restenosis.

Several paclitaxel drug-eluting balloons (DEBs) are currently available on the European market, and several others are in development. There are currently no DEBs available in the United States.

In 2009, Invatec launched four DEBs in Europe. The In.Pact Amphirion is designed to treat atherosclerosis in arteries located below the knee. The In.Pact Admiral targets the superficial femoral arteries. The In.Pact Pacific is a 0.018-inch peripheral DEB. The peripheral products offer a size range from 3 to 7 mm diameters, and balloon lengths ranging from 40 to 120 mm. The In.Pact Falcon also was released for coronary vessels.

Medtronic purchased Invatec earlier this year to expand its offerings in peripheral artery disease (PAD) treatments.

B. Braun introduced its SeQuent Please coronary DEB last year in Europe. It uses the Paccocath balloon coating matrix licensed through Bayer AG.

The Dior DEB made by EuroCor was the first DEB to earn a CE mark clearance in 2007. The drug is embedded in its microporous balloon surface, which elutes during a one-minute balloon expansion. A newer generation balloon uses shellac as a carrier.

Aachen Resonance GmbH offers the Elutax DEB in Europe for coronary and small vessels. It also uses a microporous surface.

The Acrostak Genie catheter drug delivery system has two small balloons at the distal and proximal ends of the device. They are inflated under low pressure and the occluded area is flushed with paclitaxel. After an exposure of two minutes, studies revealed the growth of stenosis is permanently inhibited.

Works in Progress

In January 2009, Micell Technologies entered into an agreement with EuroCor to develop a new generation of DEBs. The specific terms of the agreement were not disclosed, but the deal is likely aimed at creating an improved Dior DEB. Micell has developed a unique bioabsorbable polymer coating that is absorbed concurrently with the drug delivery. The technology allows both the polymer and drug to be eliminated within 90 days.

The Genesis DESA (Drug Eluting Scoring Angioplasty), from Genesis Technologies, uses a nitinol mesh braid over the DEB. The braid is supposed to create microfractures in the plaque for better drug delivery.
In the summer of 2009, Lutonix Inc. began patient enrollment for its three simultaneous first-in-human clinical trials to test its Lutonix drug coated balloon catheter. The PERVIDEO I Registry is investigating the DEB’s use in treating coronary bare metal stent in-stent restenosis. The LEVANT I Trial is examining its use in preventing restenosis in the femoropopliteal arteries. The Lutonix De Novo Pilot Study will assess the interaction between bare metal stents and the DEB.

Medrad’s Cotavance DEB uses the Paccocath balloon coating matrix technology from its parent company, Bayer AG. Medrad has submitted a clinical trial request with the U.S. Food and Drug Administration (FDA) and hopes to begin the trial in late 2010.

Cook Medical is currently in European trials with its Advance PTX drug-eluting balloon.
Boston Scientific said it also is developing a paclitaxel-eluting DEB to treat peripheral vessels.
DSM Biomedical develops both medical device coatings and drug delivery coatings, which it is using to create new DEBs.

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons| August 29, 2017
C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (...
Overlay Init